These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26241947)

  • 21. Profiling of the antibody response to attenuated LC16m8 smallpox vaccine using protein array analysis.
    Eto A; Fujita M; Nishiyama Y; Saito T; Molina DM; Morikawa S; Saijo M; Shinmura Y; Kanatani Y
    Vaccine; 2019 Oct; 37(44):6588-6593. PubMed ID: 31540810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
    Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
    J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of a vaccinia virus strain used to produce smallpox vaccine in Argentina between 1937 and 1970.
    Lewis A; Bok K; Perez O; DeFillippo J; Paolazzi C; Gomez JA
    Arch Virol; 2005 Jul; 150(7):1485-91. PubMed ID: 15750861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine: vaccinia Tiantan strain.
    Lu B; Yu W; Huang X; Wang H; Liu L; Chen Z
    J Biomed Biotechnol; 2011; 2011():970424. PubMed ID: 21765641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
    Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
    Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate.
    Ferrier-Rembert A; Drillien R; Meignier B; Garin D; Crance JM
    Vaccine; 2007 Nov; 25(49):8290-7. PubMed ID: 17964011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
    Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D
    Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
    Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
    J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.
    Hooper JW; Thompson E; Wilhelmsen C; Zimmerman M; Ichou MA; Steffen SE; Schmaljohn CS; Schmaljohn AL; Jahrling PB
    J Virol; 2004 May; 78(9):4433-43. PubMed ID: 15078924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
    Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
    Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene.
    Laassri M; Meseda CA; Williams O; Merchlinsky M; Weir JP; Chumakov K
    J Med Virol; 2007 Jun; 79(6):791-802. PubMed ID: 17457926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Smallpox subunit vaccine produced in Planta confers protection in mice.
    Golovkin M; Spitsin S; Andrianov V; Smirnov Y; Xiao Y; Pogrebnyak N; Markley K; Brodzik R; Gleba Y; Isaacs SN; Koprowski H
    Proc Natl Acad Sci U S A; 2007 Apr; 104(16):6864-9. PubMed ID: 17428917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.
    Volz A; Jany S; Freudenstein A; Lantermann M; Ludwig H; Sutter G
    Viruses; 2018 Jan; 10(1):. PubMed ID: 29300297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.
    Dimier J; Ferrier-Rembert A; Pradeau-Aubreton K; Hebben M; Spehner D; Favier AL; Gratier D; Garin D; Crance JM; Drillien R
    J Virol; 2011 May; 85(10):5016-26. PubMed ID: 21367889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.
    Kidokoro M; Shida H
    Vaccines (Basel); 2014 Oct; 2(4):755-71. PubMed ID: 26344890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA).
    Abdalrhman I; Gurt I; Katz E
    Vaccine; 2006 May; 24(19):4152-60. PubMed ID: 16603280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge.
    Edghill-Smith Y; Bray M; Whitehouse CA; Miller D; Mucker E; Manischewitz J; King LR; Robert-Guroff M; Hryniewicz A; Venzon D; Meseda C; Weir J; Nalca A; Livingston V; Wells J; Lewis MG; Huggins J; Zwiers SH; Golding H; Franchini G
    J Infect Dis; 2005 Feb; 191(3):372-81. PubMed ID: 15633096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
    Wyatt LS; Earl PL; Eller LA; Moss B
    Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
    Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD
    Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.